Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been newly diagnosed with multiple myeloma, based on internationally recognised diagnostic guidelines
- People between 18 and 70 years of age
- People whose myeloma showed a very strong response to 4–6 rounds of initial treatment, including reaching a level where cancer cells are extremely difficult to detect using a highly sensitive laboratory test
- People whose general physical functioning is rated as good to mildly limited at the time of enrolling (rated 0–2 on a standard medical scale)
- People whose liver, kidney, and heart are functioning within acceptable ranges as measured by specific blood and heart tests (confirm specific values with the trial site)
- People who are expected to survive for more than 3 months
Who may not be able to join:
- People who have two or more high-risk genetic changes in their myeloma cells, as identified by a specific chromosome analysis test (confirm details with the trial site)
- People whose myeloma has spread outside the bone marrow, affected the central nervous system, or developed into plasma cell leukaemia
- People who have had another cancer in the past 5 years
- People living with HIV, active tuberculosis, or currently active hepatitis A, B, or C
- People with serious ongoing health conditions such as severe infection, uncontrolled diabetes, significant heart failure, or unstable chest pain
- People whose overall health is considered unsuitable for chemotherapy
- People who are pregnant or breastfeeding
- People with serious disease affecting other organs, or serious mental health disorders
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Haitao Meng, Zhejiang University
Phone: +86 15088687797
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
progression free survival
Can't join this trial?
Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.